KatzH.I., HienN.T., PrawerS.E.. Super-potent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function.J Am Acad Dermatol1987; 16: 804–11.
2.
GipL., HamfeltA.Studies on the efficacy and adrenal effects of Diprolene ointment 0.05% and Dermovate ointment 0.05% in patients with psoriasis or other resistant dermatoses.Cutis1984; 33: 215–23.
3.
OlsenE.A., CramD.L., EllisC.N.A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.J Am Acad Dermatol1991; 24: 443–7.
4.
HillstromL., PetterssonL., SvenssonL.Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp.J Inter Med Res1982; 10: 419–22.
5.
WalshP., AelingJ.L., HuffL.. Hypothalamic-pituitary-adrenal axis suppression by superpotent topical steroids.J Am Acad Dermatol1993; 29(3): 501–3.
6.
MeynadierJ., GuillotB.Pituitary adrenal axis activity during topical treatment with 0.075% triamcinolone benetonide cream.Dermatologica1982; 164: 327–30.
7.
KeipertJ., KellyR.Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate.Med J of Australia1971; 1: 542–44.
8.
CookL., FreinkelR.K., ZugermanC.. Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria.J Amer Acad Dermatol1982; 6: 1054–60.
9.
BurtonT.T., CunliffeW.J., HoltiG.. Complications of topical corticosteroid therapy in patients with liver disease.Br J Dermatol1975; 91(10): 22–23.
10.
OhmanE.M., RogersS., MeenanO.F.. Adrenal suppression following low-dose topical clobetasol propionate.J Royal Soc Med1987; 80: 422–24.
